Comparative Efficacy and Safety of Tirzepatide versus Semaglutide: A Systematic Review and Meta-Analysis with Cardiometabolic Implications.
This systematic review and meta-analysis pooled data from three head-to-head randomized or controlled trials comparing tirzepatide (a dual GIP/GLP-1 receptor agonist) with semaglutide (a selective GLP-1 receptor agonist) in adults with obesity and/or type 2 diabetes. Studies were identified through searches of PubMed, Embase, and ScienceDirect up to February 2026. Using a random-effects model, the authors found that tirzepatide was associated with significantly greater weight reduction compared to semaglutide (pooled mean difference: −5.19 kg) and a higher likelihood of achieving ≥10% weight loss (pooled risk ratio: 1.50). No statistically significant differences were observed in overall adverse events or gastrointestinal events between the two agents; however, serious adverse events were reported more frequently with tirzepatide (risk ratio: 1.83). Key limitations include a very small number of included studies (n=3), substantial statistical heterogeneity in weight-related outcomes (I² >86%), and insufficient follow-up duration to draw conclusions about long-term cardiovascular safety. The authors note that further studies with longer follow-up are needed to confirm the cardiometabolic safety profile of tirzepatide relative to semaglutide.
Why this grade: Although the meta-analysis pools human trial data, the grade is moderate rather than strong due to only three included studies, high heterogeneity (I²>86%), and insufficient follow-up to assess cardiovascular outcomes.
Background Obesity and type 2 diabetes are significant global health problems. Tirzepatide, a dual GIP/GLP-1 receptor agonist, and semaglutide, a selective GLP-1 receptor agonist, are the top incretin therapy options, but their relative effectiveness and safety based on direct head- to -head studies have not been pooled. This meta-analysis aims to compare the efficacy and safety of tirzepatide versus semaglutide. Methods PubMed, Embase, and ScienceDirect were searched up to February 2026 to find the articles. Mean differences (MD) and risk ratios (RR) were pooled using a random-effects model and heterogeneity was measured using I 2 . Results Three studies were included. Tirzepatide caused significantly greater reduction in weight than semaglutide (pooled MD = -5.19 kg, 95% CI: -7.96 to -2.42; p = 0.0002; I 2 = 88.5%) and increased the possibility of ≥10% weight loss (pooled RR = 1.50, 95% CI: 1.15-1.96; p = 0.0069; I 2 = 86.3%). No significant difference was observed in any adverse events, or gastrointestinal events; however, there was a greater number of serious adverse events with tirzepatide (RR = 1.83, 95% CI: 1.18-2.85; p = 0.007). Conclusion Tirzepatide can provide better weight loss than semaglutide with relatively similar safety, except that serious adverse events were more frequent. Studies with long follow-up are required to confirm the cardiovascular safety.
Educational summary of published research — not medical advice. License: cc by. Full text is shown only where licensing permits.